Barclays Raises Humana (NYSE:HUM) Price Target to $270.00

Humana (NYSE:HUM) had its target price raised by Barclays from $255.00 to $270.00 in a research report report published on Thursday morning,Benzinga reports. Barclays currently has an equal weight rating on the insurance provider’s stock.

Several other equities research analysts also recently weighed in on the company. Wells Fargo & Company cut their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price objective on shares of Humana in a report on Wednesday. TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Wednesday. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average target price of $293.05.

Humana Trading Down 2.7 %

Shares of HUM stock opened at $252.92 on Thursday. The stock’s fifty day moving average price is $272.44 and its two-hundred day moving average price is $295.47. The company has a market cap of $30.45 billion, a PE ratio of 22.40, a P/E/G ratio of 2.11 and a beta of 0.56. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts predict that Humana will post 16.11 EPS for the current fiscal year.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC increased its position in Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock valued at $6,916,000 after buying an additional 26,856 shares in the last quarter. Retirement Systems of Alabama increased its position in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after buying an additional 192,801 shares in the last quarter. PDT Partners LLC increased its position in Humana by 190.0% in the 3rd quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock valued at $1,286,000 after buying an additional 2,660 shares in the last quarter. Secure Asset Management LLC bought a new stake in Humana in the 4th quarter valued at about $244,000. Finally, Ontario Teachers Pension Plan Board increased its position in Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after buying an additional 71,910 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.